Kolexia
Chevallier Patrice Hématologie
Chevallier Patrice
Hématologie
Hôpital Hôtel-Dieu Nantes
Nantes, France
773 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Maladie du greffon contre l'hôte Leucémie myéloïde Leucémie-lymphome lymphoblastique à précurseurs B et T Lymphomes Syndromes myélodysplasiques Tumeurs hématologiques Maladie aigüe

Collaborateurs

Voir plus
Mohty Mohamad
Mohty Mohamad
Hôpital Saint-Antoine, Paris, France
Blaise Didier
Blaise Didier
Centre Paoli-Calmettes, Marseille, France
Guillaume Thierry
Guillaume Thierry
Hôpital Hôtel-Dieu Nantes, Nantes, France
Peterlin Pierre
Peterlin Pierre
Hôpital Hôtel-Dieu Nantes, Nantes, France

Industries

Voir plus
Takeda Pharmaceutical
4 collaboration(s)
Dernière en 2021
MEDAC SAS
3 collaboration(s)
Dernière en 2022
IMMEDICA PHARMA FRANCE SARL
3 collaboration(s)
Dernière en 2023
Sanofi
3 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia.
Blood   07 mars 2024
MO-TRANS: Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT
Essai Clinique (Priothera SAS)   01 mars 2024
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study)
Essai Clinique (Amgen)   01 mars 2024
Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT.
Blood advances   01 mars 2024
Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT.
American journal of hematology   22 février 2024
Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
Blood cancer journal   19 février 2024
Trends in Allogeneic Transplantation for Favorable Risk Acute Myeloid Leukemia in First Complete Remission: A Longitudinal Study of > 15 Years from the ALWP/EBMT
Abstracts from the 2024 Tandem Meetings of ASTCT and CIBMTR, February 21-24, 2024, San Antonio, Texas, USA   01 février 2024
On behalf of the SFGM-TC: Real-life use of third-party virus-specific T-cell transfer in immunocompromised transplanted patients.
HemaSphere   27 janvier 2024
VOYAGE: A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
Essai Clinique (MacroGenics)   24 janvier 2024
Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry.
Journal of hematology & oncology   07 janvier 2024